« Return to News | CROs/Service Providers

Covance Profits Down 3% in Q1 as Central Lab Division Suffers Project Delays

Thursday, April 29, 2010 08:09 AM

Covance’s revenues grew and income fell in the first quarter of 2010. The company’s first quarter net revenues were $481.9 million, a 9.2% increase over the same period last year. Net income for the quarter fell 2.9% to $39.1 million, or $0.60 diluted EPS, compared with $40.3 million, or $0.63 diluted EPS, in Q1 2009.

Covance said strong performance from its early- and late-stage clinical development divisions helped offset a weak quarter in central laboratories stemming from slower startup of some new trials.

The company already announced plans to close two underperforming sites this quarter, which will eliminate 200 jobs and result in a cost of approximately $0.09 per share in the second quarter. 

"As a result of these cost actions (and related savings), coupled with the headwinds created by a stronger U.S. dollar, and delays in the commencement of late-stage studies, we are adjusting our 2010 revenue growth rate expectation to the 5%-8% range and our earnings per share target to $2.40 to $2.65,” said Covance chairman and CEO Joe Herring. 

The CRO had originally forecasted 10% revenue growth for 2010 with earnings per share to be in the range of $2.50 to $2.75

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.